Epidemiology of Adult Pleural Disease in the United States
- PMID: 34023322
- DOI: 10.1016/j.chest.2021.05.026
Epidemiology of Adult Pleural Disease in the United States
Abstract
Background: Comprehensive US epidemiologic data for adult pleural disease are not available.
Research question: What are the epidemiologic measures related to adult pleural disease in the United States?
Study design and methods: Retrospective cohort study using Healthcare Utilization Project databases (2007-2016). Adults (≥ 18 years of age) with malignant pleural mesothelioma, malignant pleural effusion, nonmalignant pleural effusion, empyema, primary and secondary spontaneous pneumothorax, iatrogenic pneumothorax, and pleural TB were studied.
Results: In 2016, ED treat-and-discharge (T&D) visits totaled 42,215, accounting for charges of $286.7 million. In 2016, a total of 361,270 hospitalizations occurred, resulting in national costs of $10.1 billion. A total of 64,174 readmissions contributed $1.16 billion in additional national costs. Nonmalignant pleural effusion constituted 85.5% of ED T&D visits, 63.5% of hospitalizations, and 66.3% of 30-day readmissions. Contemporary sex distribution (male to female ratio) in primary spontaneous pneumothorax (2.1:1) differs from older estimates (6.2:1). Decadal analyses of annual hospitalization rates/100,000 adult population (2007 vs 2016) showed a significant (P < .001) decrease for malignant pleural mesothelioma (1.3 vs 1.09, respectively), malignant pleural effusion (33.4 vs 31.9, respectively), iatrogenic pneumothorax (17.9 vs 13.9, respectively), and pleural TB (0.20 vs 0.09, respectively) and an increase for empyema (8.1 vs 11.1, respectively) and nonmalignant pleural effusion (78.1 vs 100.1, respectively). Empyema hospitalizations have high costs per case ($38,591) and length of stay (13.8 days). The mean proportion of readmissions attributed to a pleural cause varied widely: malignant pleural mesothelioma, 49%; malignant pleural effusion, 45%; nonmalignant pleural effusion, 31%; empyema, 27%; primary spontaneous pneumothorax, 27%; secondary spontaneous pneumothorax, 27%; and iatrogenic pneumothorax, 20%. Secondary spontaneous pneumothorax had the shortest time to readmission in 2016 (10.3 days, 95% CI, 8.8-11.8 days).
Interpretation: Significant epidemiologic trends and changes in various pleural diseases were observed. The analysis identifies multiple opportunities for improvement in management of pleural diseases.
Keywords: empyema; epidemiology (pulmonary); mesothelioma; pleural TB; pleural diseases; pleural effusion; pneumothorax.
Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Surgical Management of Pneumothorax and Pleural Space Disease.Surg Clin North Am. 2022 Jun;102(3):413-427. doi: 10.1016/j.suc.2022.03.001. Surg Clin North Am. 2022. PMID: 35671764 Review.
-
Early Readmission to Hospital in Patients With Cancer With Malignant Pleural Effusions: Analysis of the Nationwide Readmissions Database.Chest. 2020 Feb;157(2):435-445. doi: 10.1016/j.chest.2019.09.007. Epub 2019 Sep 19. Chest. 2020. PMID: 31542449
-
Characteristics and factors associated with treatment delay in pleural tuberculosis.QJM. 2018 Nov 1;111(11):779-783. doi: 10.1093/qjmed/hcy167. QJM. 2018. PMID: 30053223
-
The Global Burden of Pleural Diseases.Semin Respir Crit Care Med. 2023 Aug;44(4):417-425. doi: 10.1055/s-0043-1769614. Epub 2023 Jun 1. Semin Respir Crit Care Med. 2023. PMID: 37263289
-
Pleural complications in the intensive care unit.Clin Chest Med. 1999 Jun;20(2):317-27. doi: 10.1016/s0272-5231(05)70144-1. Clin Chest Med. 1999. PMID: 10386259 Review.
Cited by
-
Malignant pleural effusion: current understanding and therapeutic approach.Respir Res. 2024 Jan 19;25(1):47. doi: 10.1186/s12931-024-02684-7. Respir Res. 2024. PMID: 38243259 Free PMC article. Review.
-
Infective Pleural Effusions-A Comprehensive Narrative Review Article.Clin Pract. 2024 May 16;14(3):870-881. doi: 10.3390/clinpract14030068. Clin Pract. 2024. PMID: 38804400 Free PMC article. Review.
-
Risk factors and prognostic predictors of recurrent bacterial empyema in patients after surgical treatment.BMC Infect Dis. 2025 May 6;25(1):667. doi: 10.1186/s12879-025-11077-0. BMC Infect Dis. 2025. PMID: 40329238 Free PMC article.
-
Ultrasound and Intrapleural Enzymatic Therapy for Complicated Pleural Effusion: A Case Series with a Literature Review.J Clin Med. 2024 Jul 25;13(15):4346. doi: 10.3390/jcm13154346. J Clin Med. 2024. PMID: 39124612 Free PMC article. Review.
-
Burden of all-cause and organism-specific parapneumonic empyema hospitalization rates prior to the SARS-CoV-2 pandemic in the United States.Respir Med. 2023 Feb;207:107111. doi: 10.1016/j.rmed.2022.107111. Epub 2022 Dec 31. Respir Med. 2023. PMID: 36592639 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical